Pharmaceutical and biotechnology company Symbiotec Pharmalab Limited has filed draft IPO documents with SEBI for a public issue aggregating ₹2,180 crore.
The proposed issue consists of a ₹150 crore fresh issue and an offer for sale of ₹2,030 crore by selling shareholders. The equity shares are proposed to be listed on the NSE and BSE.
According to the DRHP, the company will deploy proceeds from the fresh issue towards repayment or prepayment of borrowings and for general corporate purposes.
Symbiotec Pharmalab is an R&D-focused company with manufacturing capabilities across organic chemistry and biotechnology. As per the F&S Report cited in the DRHP, it holds a 44.2% global market share in steroidal-hormone APIs by volume in FY25.
